SCHEMBL338955

SCHEMBL338955

CCCCOC([O])CCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
ALDH1A1 P00352 1/20 0.37
DNM1 Q05193 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ATM Q13315 1/20 0.34
TSHR P16473 4/20 0.33
ZDHHC7 Q9NXF8 1/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
LCK P06239 1/20 0.32
PPARD Q03181 1/20 0.32
ZDHHC20 Q5W0Z9 1/20 0.32
ZDHHC2 Q9UIJ5 1/20 0.32
LPAR1 Q92633 2/20 0.32
LPAR3 Q9UBY5 2/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2671093 0.92 DNM1 (0.45) DNM1CA1CA2LPAR1LPAR3
SCHEMBL2670811 0.90 DNM1 (0.48) DNM1CA1CA2ZDHHC7LPAR1
SCHEMBL2670936 0.90 CYP3A4 (0.39) CYP3A4ADRB2ADRB1ADRB3ALDH1A1
SCHEMBL2670949 0.87 ZDHHC7 (0.41) CYP3A4ADRB2ADRB1ADRB3ALDH1A1
SCHEMBL7339342 0.85 ZDHHC7 (0.44) DNM1TSHRZDHHC7LCKPPARD
SCHEMBL7337862 0.85 ZDHHC7 (0.44) DNM1TSHRZDHHC7LCKPPARD
SCHEMBL4398367 0.84 TSHR (0.37) CYP3A4ADRB2ADRB1ADRB3ALDH1A1
SCHEMBL2671071 0.83
SCHEMBL5961100 0.83 ALDH1A1 (0.33) ALDH1A1LMNA
SCHEMBL4391336 0.83 ADRB2 (0.34) CYP3A4ADRB2ADRB1ADRB3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4374877-A2 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-29 EP disclosed
US-11932715-B2 Hardmask composition and method of forming patterns SAMSUNG SDI CO., LTD. (KR) 2024-03-19 US disclosed
EP-3928779-B1 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-03-06 EP disclosed
US-11814393-B2 Substituted guanidine compounds UBE CORPORATION (JP) 2023-11-14 US disclosed
CN-114660897-A Hardmask composition and method of forming pattern 三星SDI株式会社 2022-06-24 CN disclosed
US-20220195082-A1 HARDMASK COMPOSITION AND METHOD OF FORMING PATTERNS SAMSUNG SDI CO., LTD. (KR) 2022-06-23 US disclosed
CN-110114350-B Substituted guanidine compounds 宇部兴产株式会社 2022-03-04 CN disclosed
EP-3564230-B1 SUBSTITUTED GUANIDINE COMPOUND UBE INDUSTRIES (JP) 2022-02-09 EP disclosed
EP-3928779-A1 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. Chugai Seiyaku Kabushiki Kaisha (JP) 2021-12-29 EP disclosed
EP-3192511-B1 PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-07-14 EP disclosed
EP-0226641-B1 OXODIAZINE COMPOUNDS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1989-10-18 EP disclosed
US-4840951-A ANTILIPEMIC AGENTS TANABE SEIYAKU CO., LTD. (JP) 1989-06-20 US disclosed
EP-0251315-A2 Naphthalene derivatives, process for their preparation and pharmaceutical compositions containing the same TANABE SEIYAKU CO., LTD. (JP) 1988-01-07 EP disclosed
US-4713381-A ANTICOAGULANTS, ANALGESICS, ANTIINFLAMMATORY AGENT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1987-12-15 US disclosed
EP-0226641-A1 OXODIAZINE COMPOUNDS. YOSHITOMI PHARMACEUTICAL (JP) 1987-07-01 EP disclosed
WO-1986007059-A2 OXODIAZINE COMPOUNDS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1986-12-04 WO disclosed
EP-0028137-B1 DRY PLANOGRAPHIC PRINTING PLATE TORAY INDUSTRIES, INC. (JP) 1984-12-05 EP disclosed
US-4308799-A POLYSILOXANE, ALKOXYSILANE, AND ORGANOTITANIUM OR ZIRCONIUM COMPOUND TORAY INDUSTRIES, INC. (JP) 1982-01-05 US disclosed
EP-0028137-A1 Dry planographic printing plate TORAY INDUSTRIES, INC. (JP) 1981-05-06 EP disclosed
US-3988142-A Increasing carbohydrate deposition in plants with N-phosphono-methylglycine and derivatives thereof MONSANTO COMPANY (US) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814393-B2 Substituted guanidine compounds GMPS, PDE3B, GUCY1A2 CYP3A4 302/4885ADRB2 233/4885ADRB1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.